Marc Andreessen's a16z Invests $465 Million in Navan's Corporate Spending Platform, According to Recent SEC Filing
Source: Motley Fool
2026-02-18 15:50:42 ET
According to its SEC filing dated February 17, 2026, a16z Capital Management, L.L.C. established a new position in Navan (NASDAQ:NAVN) by acquiring roughly 27 million shares during the fourth quarter. The estimated transaction value is $464.50 million, calculated using the average share price over the quarter. The quarter-end value of the stake also stood at $464.50 million, reflecting the addition of the new position.
This is a new position for the fund, representing 29.4% of its 13F reportable assets under management at the end of 2025
Top holdings after the filing:
Maze Therapeutics Inc.
NASDAQ: MAZE
MAZE Trading
8.81% G/L:
$48.56 Last:
269,438 Volume:
$46.29 Open:
MAZE Latest News
February 25, 2026 07:00:00 am
Maze Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference
February 18, 2026 03:50:42 pm
Marc Andreessen's a16z Invests $465 Million in Navan's Corporate Spending Platform, According to Recent SEC Filing
February 16, 2026 01:55:14 am
Maze Therapeutics Chief Medical Officer Sells 15K Shares As Company's Stock Continues to Surge
February 04, 2026 07:00:00 am
Maze Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
MAZE Stock Data
$2,327,537,506
23,771,005
0.82%
31
N/A
Biotechnology & Life Sciences
Healthcare
US
South San Francisco
